Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
Creating novel bispecific antibodies that activate the immune system to fight cancer
Eyebiotech is a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.
Perfuze is a medical device company based in Galway, Ireland, founded in 2018 by Wayne Allen and Liam Mullins. Specializing in innovative catheter technology, Perfuze aims to treat acute ischemic stroke, a condition that can lead to severe health complications if not addressed promptly. The company’s technology is designed to improve clinical outcomes while reducing procedural times, making the treatment safer and more cost-effective for patients. With over 30 years of combined experience in the medtech industry, the founders are focused on developing solutions that minimize the need for alternative treatment options during procedures. Perfuze is currently located in the Business Innovation Centre at the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.
Eyebiotech is a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
Developer of a biotechnology research and development platform designed to offer therapeutics for the treatment of cancer and inflammatory diseases. The company's platform exploits emerging insights related to the role of activated fibroblast populations in disease for developing therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and cancer, enabling the medical industry to combat and cure rare and life-threatening diseases.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
Health Payment Systems, Inc. is a healthcare company based in Milwaukee, Wisconsin, that specializes in simplifying the healthcare payment process for patients, providers, and employers. Founded in 2005, the company leverages electronic data exchange technology to process, consolidate, and transmit claims and payment information among stakeholders. HPS offers the Single Payment System, which enables hospitals and physicians to receive payments for both employers' and employees' portions of claims in a single electronic transaction. Additionally, the HPS SuperEOB provides a monthly billing statement that aggregates and clarifies various healthcare claims for individuals and families, enhancing transparency regarding costs and insurance coverage. HPS has formed a strategic alliance with Trilogy Health Networks to further its mission of improving the consumer experience in healthcare payments.
Leiters Compounding Pharmacy, founded in 1925 and based in San Jose, California, is a FDA-registered 503B outsourcing provider specializing in high-quality ophthalmology and hospital-based pharmaceutical care. The company manufactures and sells a range of specialty compounding products, including ophthalmic solutions, autologous serums, and various sterile medications tailored for universities, hospitals, and health organizations across the United States. By leveraging a team of experts in sterile pharmaceutical manufacturing and utilizing state-of-the-art facilities, Leiters ensures the highest standards of quality and consistency in their products. They prioritize the well-being of patients, who have relied on Leiters for nearly a century. Customers can conveniently order products online, enhancing access to essential medications.
Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
AavantiBio, Inc. is dedicated to developing gene transfer therapy and gene editing technologies aimed at improving the lives of individuals afflicted by rare and fatal diseases. The company primarily focuses on Friedreich’s Ataxia, a rare inherited genetic disorder that leads to significant cardiac and central nervous system dysfunction. Founded in 2019 and based in Gainesville, Florida, AavantiBio is committed to advancing innovative gene therapies to address unmet medical needs in the treatment of rare genetic diseases and autoimmune conditions. Through its research and development efforts, the company seeks to transform patient care and enhance treatment options for those affected by these serious health challenges.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
Cellinta Limited is a biotechnology company focused on the research and development of gene therapies aimed at treating cancer. Founded in 2019 and headquartered in London, United Kingdom, Cellinta specializes in stem cell-based therapies to address brain cancers and other solid tumors. The company has created a platform that allows for the selective elimination of neural stem cells, utilizing computational tools and patient-derived cancer stem cell models. These innovations enable the identification of cancer stem cell-specific regulatory circuits, providing valuable insights and strategies for the medical community to combat cancer more effectively.
Evidation Health develops a health data analytics platform that collects and analyzes continuous behavior data alongside healthcare information to enhance health outcomes. Founded in 2012 and headquartered in San Mateo, California, the company utilizes raw, high-frequency data from various sources such as sensors, devices, and video to generate insights into health and disease. Its products include a Data Platform, which transforms everyday behavior data into actionable health measures, and Studies, a service for conducting real-world research that incorporates behavioral data to support clinical and commercial teams. Evidation Health connects digital health companies with healthcare providers and payers, facilitating a better understanding of how everyday behaviors influence health. The company's offerings also encompass health outcomes research, technology assessment, and predictive analytics services.
Amwell is a telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 150 million lives. Amwell was founded in 2006 and is headquartered in Boston, Massachusetts.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
Transposon Therapeutics
Seed Round in 2020
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseases
CytoMed Therapeutics is a cancer immunotherapy startup.
EBT Medical, Inc. is a clinical-stage company focused on developing non-invasive neuromodulation therapies for pelvic health disorders, particularly targeting overactive bladder issues. Founded in 2014 and headquartered in Boston, Massachusetts, with an additional office in Toronto, Canada, the company emerged from scientific research conducted at the University of Toronto. EBT Medical's innovative technology aims to provide discreet treatment options that restore pelvic health function without the side effects commonly associated with traditional therapies. The company is part of a broader ecosystem designed to support patients with pelvic floor disorders.
Ervaxx is pioneering the use of Dark Antigens™ to deliver targeted off-the-shelf cancer vaccines and other immunotherapies for treating and preventing cancer. Their Dark Antigens™ derive from vast untapped expanses of genetic ‘dark matter’ beyond the normal coding regions of the genome, which are generally silenced in normal tissue but are selectively activated in cancer.
Healthify, Inc. specializes in developing software solutions that address social determinants of health for healthcare organizations, including health plans, hospitals, and provider networks. Founded in 2013 and headquartered in New York, the company offers a comprehensive platform that includes tools for searching community resources, tracking population needs and referrals, coordinating efforts among key partners, and measuring health outcomes. By fostering collaboration among community-based organizations and streamlining the referral process, Healthify aims to improve the overall health of populations, particularly in low-income communities. The platform supports accountable networks and is designed to demonstrate the return on investment for social service interventions, ensuring that families receive essential services to thrive.
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.
Private Equity Round in 2019
AeroCare Direct is a company based in Orlando, Florida, that specializes in distributing home medical equipment across the United States. It provides a range of products focused on respiratory therapy, including oxygen machines, CPAP/BiPAP devices, nebulizers, and associated supplies. The company caters primarily to patients suffering from chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), and Obstructive Sleep Apnea (OSA). In addition to respiratory products, AeroCare Direct also offers durable medical equipment such as wheelchairs, walkers, and canes. Notably, AeroCare Direct allows patients to purchase CPAP and respiratory supplies directly, offering an alternative to insurance-based transactions, which can often be costly or limited.
Bardy Diagnostics, Inc. is a medical device company that specializes in the development and manufacturing of cardiac monitoring solutions, primarily focused on arrhythmia detection. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight, discreet cardiac patch that can be worn comfortably for up to seven days, even during physical activities like exercise or showering. The CAM is designed with a unique hourglass shape to enhance comfort, particularly for female patients. Complementing the monitor is the BDxCONNECT patient management system, which allows healthcare providers to create and manage patient reports efficiently. By utilizing innovative P-wave centric ECG detection technology, Bardy Diagnostics aims to improve clinical management and outcomes for patients and their physicians. Founded in 2013, the company is headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey.
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.
Operator of an orthodontist support platform intended for orthodontists and supporting teams. The company's platform partners with orthodontists and provides them support like marketing, staff recruitment and training, office management, billing and collections, capital management, and succession planning, enabling practice partners to solve many practice transition challenges.
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.
Urgent Team Holdings, Inc. operates a network of urgent care centers that deliver both urgent and primary health care services. These facilities cater to a diverse range of medical needs, including treatment for sprains, strains, broken bones, muscular injuries, eye irritations, cuts, bites, burns, infections, and various illnesses such as flu and pneumonia. In addition to urgent care, Urgent Team provides preventative screenings and wellness services, including immunizations, physical exams, and diagnostic testing. The centers are designed to serve suburban neighborhoods, rural areas, and underserved communities, offering affordable and convenient walk-in medical services to enhance access to healthcare.
Sitryx Therapeutics is a biopharmaceutical company established in 2018 and based in Oxford, United Kingdom. It focuses on developing disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. The company aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by renowned scientists from the United States and Europe, Sitryx has garnered significant funding, including a $30 million Series A round from various specialist investors. The company is actively engaged in multiple stages of drug discovery, working on a diverse pipeline of projects aimed at addressing unmet medical needs in immunometabolism.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Evidation Health develops a health data analytics platform that collects and analyzes continuous behavior data alongside healthcare information to enhance health outcomes. Founded in 2012 and headquartered in San Mateo, California, the company utilizes raw, high-frequency data from various sources such as sensors, devices, and video to generate insights into health and disease. Its products include a Data Platform, which transforms everyday behavior data into actionable health measures, and Studies, a service for conducting real-world research that incorporates behavioral data to support clinical and commercial teams. Evidation Health connects digital health companies with healthcare providers and payers, facilitating a better understanding of how everyday behaviors influence health. The company's offerings also encompass health outcomes research, technology assessment, and predictive analytics services.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Stimwave LLC is a medical device company focused on developing, manufacturing, and marketing wireless microsize injectable devices for neurology applications. The company's product offerings include the Freedom SCS System, a spinal cord stimulator designed to alleviate chronic low back and leg pain, and the StimQ PNS System, a peripheral nerve stimulator that addresses chronic pain by targeting specific peripheral nerves. Originally incorporated as Neural Micro Incorporated in 2010, Stimwave LLC is headquartered in Pompano Beach, Florida.
Centauri Health Solutions is a technology-centric company specializing in hosted software solutions, data-driven services, and data management designed specifically for risk adjustment and quality based revenue programs.
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.
LOQUS23 THERAPEUTICS
Seed Round in 2018
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.
Misonix has long been at the forefront of ultrasound technology and is a world leader in the design, development, manufacturing, and marketing of ultrasonic surgical devices. Their innovative, ultrasonic platforms for surgical applications include aspirators for the removal of both soft and hard tissue, instruments for laparoscopic cutting and coagulation, devices for wound cleansing and debridement, products for precision bone cutting and sculpting, liposuction instrumentation for improving body aesthetics, and High Intensity Focused Ultrasound (HIFU) systems for the ablation of tumors.
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Bardy Diagnostics, Inc. is a medical device company that specializes in the development and manufacturing of cardiac monitoring solutions, primarily focused on arrhythmia detection. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight, discreet cardiac patch that can be worn comfortably for up to seven days, even during physical activities like exercise or showering. The CAM is designed with a unique hourglass shape to enhance comfort, particularly for female patients. Complementing the monitor is the BDxCONNECT patient management system, which allows healthcare providers to create and manage patient reports efficiently. By utilizing innovative P-wave centric ECG detection technology, Bardy Diagnostics aims to improve clinical management and outcomes for patients and their physicians. Founded in 2013, the company is headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey.
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.
Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.
NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of therapeutics that harness the unique properties of natural killer T (NKT) cells. Incorporated in 2008, the company aims to create a pipeline of innovative NKT-based treatments targeting a range of conditions, including cancer, sickle cell disease, autoimmune disorders, inflammatory diseases, infectious diseases, asthma, and dermatitis. Through its focused research and development efforts, NKT Therapeutics strives to advance first-in-class therapies that can address unmet medical needs in these areas.
CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.
SUN Behavioral Health, Inc. operates specialized hospitals that offer a range of behavioral health services for children, youth, adults, and seniors, addressing significant unmet needs in this sector. The company provides inpatient psychiatric care, substance abuse treatment, partial hospitalization programs, and intensive outpatient programs, along with 24-hour assessments and crisis stabilization services. Additionally, SUN Behavioral Health caters to women and supports active duty and veteran military personnel. Established in 2013 and headquartered in Red Bank, New Jersey, the organization collaborates with medical and surgical hospitals, physicians, and local community entities to deliver a comprehensive continuum of care that prioritizes personalized treatment for patients and their families.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.
ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.
Maestro Health is an employee benefits company that specializes in providing integrated solutions for brokers, small employers, and Fortune 1000 organizations. Founded in 2013 and based in Chicago, Illinois, the company offers a comprehensive platform known as maestroEDGE, which includes benefits administration, enrollment, self-insurance, and healthcare savings account management. By operating a proprietary private exchange and medical third-party administrator (TPA), Maestro Health enables employers to streamline care management, ultimately reducing costs associated with employee benefits. The company was previously known as Maestro Healthcare Technology, Inc. and rebranded to Maestro Health in April 2014. As of early 2018, it operates as a subsidiary of AXA US Holdings Inc.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Private Equity Round in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma The NF-κB Pathway and Novel Oncology Target (GADD45β/MKK7), Research and Development pipeline and related indications. The company was incorporated in 2012 and is based in Cambridge, United Kingdom.
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.
SUN Behavioral Health, Inc. operates specialized hospitals that offer a range of behavioral health services for children, youth, adults, and seniors, addressing significant unmet needs in this sector. The company provides inpatient psychiatric care, substance abuse treatment, partial hospitalization programs, and intensive outpatient programs, along with 24-hour assessments and crisis stabilization services. Additionally, SUN Behavioral Health caters to women and supports active duty and veteran military personnel. Established in 2013 and headquartered in Red Bank, New Jersey, the organization collaborates with medical and surgical hospitals, physicians, and local community entities to deliver a comprehensive continuum of care that prioritizes personalized treatment for patients and their families.
Aligned Telehealth is a provider of a SaaS-based platform used to offer telemedicine and healthcare management services. Its platform offers full, end-to-end telemedicine services, including psychiatric specialty physician consultations to acute-care hospitals, emergency rooms, skilled nursing facilities, and correctional institutions that enable clients to deliver improved quality and efficient patient care.
Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.
Halscion, Inc. is focused on developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company produces single-use hydrogel scaffold devices that are injected during surgical procedures at the dermal-subdermal interface of wounds. These biocompatible materials create a structural framework that facilitates the migration and organization of the patient's own healing cells, such as fibroblasts, into the wound. This technology aims to prevent or minimize scar formation, including conditions like keloid and hypertrophic scars. Established in 2005, Halscion is headquartered in Suwanee, Georgia.
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of innovative medicines for cancer. Established in 2005, the company focuses on designing and developing orally-active small molecule drugs aimed at targeting specific molecular pathways. Its notable products include KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, designed for treating both hematological and solid tumors, and KA2507, an HDAC6 inhibitor intended for tumors expressing PD-L1. Karus Therapeutics aims to address unmet medical needs in oncology through its targeted therapeutic approaches.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
JET Health Solutions is a healthcare technology company focused on providing smart solutions for healthcare payers across the country. Our flagship product, JET Insure, is a quote-to-card (Q2C) insurance automation platform that provides individual/family plans, group plans, stop-loss/self-funded options, and specialty products on a single, cloud-based solution.
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
VHsquared Ltd. develops oral biologics for immuno-inflammatory targets in the gastro intestinal tract. The company identifies, screens, selects, and engineers Vorabodies, a transformational therapy for the treatment of inflammatory bowel disease. It uses its Vorabody platform to generate potent protease resistant domain antibodies for oral administration. The company was incorporated in 2010 and is based in Cambridge, United Kingdom.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.
AeroCare Direct is a company based in Orlando, Florida, that specializes in distributing home medical equipment across the United States. It provides a range of products focused on respiratory therapy, including oxygen machines, CPAP/BiPAP devices, nebulizers, and associated supplies. The company caters primarily to patients suffering from chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), and Obstructive Sleep Apnea (OSA). In addition to respiratory products, AeroCare Direct also offers durable medical equipment such as wheelchairs, walkers, and canes. Notably, AeroCare Direct allows patients to purchase CPAP and respiratory supplies directly, offering an alternative to insurance-based transactions, which can often be costly or limited.
Soffio Medical is a medical company that develops medical apparatus for respiratory diseases.
The company is based in Boston, Massachusetts.
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.
Maestro Health is an employee benefits company that specializes in providing integrated solutions for brokers, small employers, and Fortune 1000 organizations. Founded in 2013 and based in Chicago, Illinois, the company offers a comprehensive platform known as maestroEDGE, which includes benefits administration, enrollment, self-insurance, and healthcare savings account management. By operating a proprietary private exchange and medical third-party administrator (TPA), Maestro Health enables employers to streamline care management, ultimately reducing costs associated with employee benefits. The company was previously known as Maestro Healthcare Technology, Inc. and rebranded to Maestro Health in April 2014. As of early 2018, it operates as a subsidiary of AXA US Holdings Inc.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.